Skip to main content

Table 2 Univariate and multivariate Logistic analysis of clinical factors for predicting patients with adverse pathology

From: [68Ga]Ga‑PSMA‑617 PET-based radiomics model to identify candidates for active surveillance amongst patients with GGG 1–2 prostate cancer at biopsy

 

Univariate analysis

Multivariate analysis

 

OR (95% CI)

P value

OR (95% CI)

P value

Age (years)

0.96 (0.90–1.03)

0.270

-

-

PSA (ng/ml)

1.04 (0.99–1.09)

0.060

-

-

FPSA (ng/ml)

0.98 (0.85–1.14)

0.803

-

-

PV (ml)

1.01 (0.99–1.02)

0.337

-

-

PSAD (ng/ml2)

2.84 (0.88–9.16)

0.081

-

-

FPSA/TPSA

0.00 (0.00–0.27)

0.024*

0.00 (0.00–0.57)

0.037*

Biopsy GGG

1.79 (0.70–4.55)

0.220

-

-

% of positive cores

1.05 (0.36–3.08)

0.104

-

-

SUVmax

1.13 (1.03–1.24)

0.008*

1.70 (0.68–4.25)

0.064

SUVmean

1.22 (1.04–1.42)

0.015*

0.50 (0.10–2.47)

0.084

PSMA-TL

1.04 (1.01–1.08)

0.010*

0.98 (0.93–1.04)

0.444

PSMA-TV

1.32 (1.08–1.62)

0.007*

1.29 (1.06–1.58)

0.013*

  1. OR odds ratio, CI confidence interval, PSA prostate-specific antigen, FPSA free prostate-specific antigen, PV prostate volume, PSAD prostate-specific antigen density, TPSA total prostate-specific antigen, GGG Gleason Grade Group, SUVmax maximum standardized uptake values, SUVmean mean standardized uptake values, PSMA-TL prostate-specific membrane antigen total lesion, PSMA-TV prostate-specific membrane antigen tumour volume
  2. *P < 0.05
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us